Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

Ankylosing spondylitis (AS) is a chronic immune-mediated disease affecting the sacroiliac joints and the spine, manifesting with new bone formation and osteopenia. Five tumor necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab, and golimumab) are available for the treatment of AS, however, the results for the safety of TNF-α inhibitors in the treatment of AS are not consistent.

Methods:

In this study, we conducted a meta-analysis to determine the safety of TNF-α inhibitors compared with placebo in reducing pain, swelling, and inflammation of AS patients. Eight relevant articles including 2049 patients were included for this meta-analysis study. We observed that the incidence of adverse events (RR  =  1.22, 95% CI: 1.12–1.33; P  =  .501, I2  =  0%) and injection-site reaction (RR  =  2.93, 95% CI: 2.02–4.23; P  =  .691, I2  =  0%) in AS patients’ treatment with TNF-α inhibitors was significantly higher than that with placebo.

Results:

However, there was no significant difference in the incidence of serious adverse event, infection, serious infection, and discontinuations due to adverse event. TNF-α inhibitors may be a promising treatment for AS, but carries an increased incidence rate of adverse events and injection-site reaction.

Conclusion:

Due to the existence of the unstable factors, further studies need to be done to verify the result of this study.

Related Topics

    loading  Loading Related Articles